Gh Research PLC (GHRS) — SEC Filings

Overview

Gh Research PLC (GHRS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Mar 25, 2026: GH Research PLC filed a 6-K on March 25, 2026, which is a routine report for foreign private issuers. This specific filing includes three exhibits: the 6-K itself, Exhibit 99.1, and Exhibit 99.2, along with several image files. While the filing itself doesn't detail specific financial events, it ind

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 2 bullish, 48 neutral. The dominant filing sentiment for Gh Research PLC is neutral.

Filing Type Overview

Gh Research PLC (GHRS) has filed 1 3, 40 6-K, 1 20-F/A, 2 20-F, 4 SC 13G/A, 2 SC 13G with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• 3 Filing — 3 · Apr 1, 2026
• GH Research PLC Files Routine 6-K Report with SEC — 6-K · Mar 25, 2026
  GH Research PLC filed a 6-K on March 25, 2026, which is a routine report for foreign private issuers. This specific filing includes three exhibits: the 6-K itse
• 6-K Filing — 6-K · Nov 24, 2025
• GH Research to Present at Stifel Healthcare Conference — 6-K · Nov 7, 2025 Risk: low
  GH Research PLC announced its participation in the Stifel 2025 Healthcare Conference, taking place in New York from November 11-13, 2025. The company will engag
• 6-K Filing — 6-K · Nov 6, 2025
• GH Research PLC Trial Data Accepted at ACNP Meeting — 6-K · Oct 17, 2025 Risk: low
  GH Research PLC announced on October 17, 2025, that abstracts related to its GH001-TRD-201 clinical trial have been accepted for presentation at the 64th Americ
• GH Research Presents GH001-TRD-201 Trial Data at ECNP Meeting — 6-K · Oct 14, 2025 Risk: medium
  GH Research PLC announced on October 14, 2025, that data from its GH001-TRD-201 clinical trial was presented at the 38th European College of Neuropsychopharmaco
• GH Research to Present Clinical Trial Data at ECNP Meeting — 6-K · Oct 10, 2025 Risk: low
  GH Research PLC announced on October 10, 2025, that data from its GH001-TRD-201 clinical trial will be presented at the 38th European College of Neuropsychophar
• GH Research to Present at ECNP Meeting — 6-K · Oct 9, 2025 Risk: low
  GH Research PLC announced its participation in the 38th European College of Neuropsychopharmacology (ECNP) annual meeting, scheduled for October 11-14, 2025, in
• GH Research to Present at TD Cowen Neuropsychiatry Summit — 6-K · Sep 12, 2025 Risk: low
  GH Research PLC announced its participation in the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry and Epilepsy Summit. The company will present during
• GH Research to Present Bipolar Trial Data at ISBD Meeting — 6-K · Sep 9, 2025 Risk: low
  GH Research PLC announced on September 9, 2025, that data from its GH001-BD-202 clinical trial will be presented at the International Society for Bipolar Disord
• GH Research to Present at Cantor Global Healthcare Conference — 6-K · Aug 29, 2025 Risk: low
  GH Research PLC announced its participation in the Cantor Global Healthcare Conference, scheduled for September 3-5, 2025, in New York. The company will engage
• GH Research PLC Files 6-K with Financial Updates — 6-K · Aug 7, 2025 Risk: low
  GH Research PLC filed a 6-K report on August 7, 2025, for the period ending June 30, 2025. The filing includes financial data for the periods ending December 31
• GH Research PLC Annual Meeting: All Resolutions Passed — 6-K · Aug 1, 2025 Risk: low
  GH Research PLC held its annual general meeting on July 31, 2025, where shareholders approved all resolutions recommended by the board of directors. Notably, Fl
• 20-F/A Filing — 20-F/A · Jul 29, 2025
• GH Research PLC Announces Pivotal Program Plans — 6-K · Jul 23, 2025 Risk: medium
  On July 23, 2025, GH Research PLC announced its global pivotal program plans and provided further development updates. The company filed a Form 6-K to report th
• GH Research PLC Responds to FDA Clinical Hold for GH001 — 6-K · Jun 20, 2025 Risk: medium
  On June 20, 2025, GH Research PLC announced it submitted a complete response to the FDA regarding the clinical hold on its Investigational New Drug Application
• GH Research PLC Schedules Annual General Meeting for July 31 — 6-K · Jun 18, 2025 Risk: low
  GH Research PLC announced on June 18, 2025, a convening notice for its annual general meeting. The meeting is scheduled for July 31, 2025, at 2:00 PM Irish Stan
• GH Research to Participate in Neuro Perspectives Conference — 6-K · Jun 13, 2025 Risk: low
  GH Research PLC announced its participation in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, scheduled for June 16-17, 2025. The company
• GH Research to Present at ASCP Annual Meeting — 6-K · May 27, 2025 Risk: low
  GH Research PLC announced its participation in the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, held from May 27-30, 2025, in Scottsda
• GH Research to Present at ASCP Annual Meeting — 6-K · May 21, 2025 Risk: low
  GH Research PLC announced on May 21, 2025, that it will attend the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting from May 27-30, 2025, i
• GH Research PLC Accepted to ASCP Annual Meeting — 6-K · May 15, 2025 Risk: low
  GH Research PLC announced on May 15, 2025, that its pharmaceutical pipeline presentations and late-breaking posters have been accepted at the American Society o
• GH Research PLC Files Q1 2025 6-K Report — 6-K · May 8, 2025 Risk: low
  GH Research PLC filed a 6-K report for the period ending March 31, 2025. The filing includes financial data for the first quarter of 2025 and the full year 2024
• GH Research PLC Files 2024 Annual Report — 20-F · Feb 27, 2025 Risk: medium
  GH Research PLC filed its annual 20-F report for the fiscal year ending December 31, 2024. The company, incorporated in L2 and headquartered in Dublin, Ireland,
• GH Research PLC Completes Share Offering — 6-K · Feb 6, 2025 Risk: medium
  On February 6, 2025, GH Research PLC completed an offering of 10,000,000 ordinary shares. This offering was conducted under an underwriting agreement with Canto
• GH Research Prices $150M Public Offering — 6-K · Feb 5, 2025 Risk: medium
  GH Research PLC announced on February 4, 2025, the pricing of a public offering of its ordinary shares, raising $150 million. The offering is expected to close
• GH Research PLC's GH001 Meets Primary Endpoint in TRD Trial — 6-K · Feb 3, 2025 Risk: medium
  On February 3, 2025, GH Research PLC announced that its product candidate, GH001, an inhalable mebufotenin, met its primary endpoint in a Phase 2b clinical tria
• GH Research Plans Public Share Offering — 6-K · Feb 3, 2025 Risk: medium
  GH Research PLC announced a proposed public offering of its ordinary shares on February 3, 2025. The company, headquartered in Dublin, Ireland, is a foreign pri
• GH Research PLC Files 6-K, Updates GH001 Trial — 6-K · Jan 31, 2025 Risk: medium
  GH Research PLC filed a 6-K report on January 31, 2025, announcing an update on its Phase 2b trial for GH001. The company, headquartered in Dublin, Ireland, is
• GH Research PLC's GH001 Meets Phase 2a Endpoints, FDA Hold Addressed — 6-K · Jan 10, 2025 Risk: medium
  On January 10, 2025, GH Research PLC announced that its drug candidate GH001 met its primary endpoint in two Phase 2a Proof-of-Concept (POC) trials. The company
• GH Research to Attend Neuropsychopharmacology Meeting — 6-K · Dec 5, 2024 Risk: low
  GH Research PLC announced on December 5, 2024, that it will participate in the 63rd Annual Meeting of the American College of Neuropsychopharmacology 2024. The
• GH Research PLC Files 6-K with Q3 2024 Financials — 6-K · Nov 14, 2024 Risk: low
  GH Research PLC filed a 6-K report on November 14, 2024, detailing financial information as of September 30, 2024. The filing includes comparative balance sheet
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• GH Research PLC to Present at 37th ECNP Congress — 6-K · Sep 20, 2024 Risk: low
  GH Research PLC announced its attendance at the 37th ECNP Congress in Milan, Italy, from September 21-24, 2024. The company will sponsor an industry mini-sessio
• GH Research to Present at Cantor Global Healthcare Conference — 6-K · Sep 16, 2024 Risk: low
  GH Research PLC announced its participation in the Cantor Global Healthcare Conference, scheduled for September 17-19, 2024, in New York. The company will engag
• GH Research to Present at H.C. Wainwright Conference — 6-K · Sep 9, 2024 Risk: low
  GH Research PLC announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference, taking place from September 9-11, 2024, in New York
• GH Research PLC Files 6-K with Financial Updates — 6-K · Sep 3, 2024 Risk: low
  GH Research PLC filed a 6-K report on September 3, 2024, detailing financial information for the period ending June 30, 2024. The filing includes balance sheet
• GH Research PLC Shareholders Approve All Board Resolutions — 6-K · Jun 28, 2024 Risk: low
  On June 27, 2024, GH Research PLC held its annual general meeting where shareholders approved all resolutions recommended by the board of directors. The company
• GH Research PLC to Present at Two Healthcare Conferences — 6-K · Jun 24, 2024 Risk: low
  GH Research PLC announced on June 24, 2024, that it will participate in investor meetings at the Stifel European Healthcare Summit in Lyon, France, from June 25
• GH Research PLC Schedules Annual General Meeting for June 27 — 6-K · May 15, 2024 Risk: low
  GH Research PLC announced on May 15, 2024, a convening notice for its annual general meeting scheduled for June 27, 2024, at 2:00 p.m. Irish Standard Time in Du
• GH Research PLC Q1 2024 6-K Filing — 6-K · May 3, 2024 Risk: low
  GH Research PLC filed a 6-K report for the period ending March 31, 2024. The filing includes financial data for the first quarter of 2024 and the full year 2023
• GH Research to Attend Life Sciences Conference — 6-K · Apr 10, 2024 Risk: low
  GH Research PLC announced on April 10, 2024, that it will participate in Van Lanschot Kempen's Life Sciences Conference in Amsterdam from April 16-17, 2024. The
• GH Research to Participate in Stifel Virtual CNS Days — 6-K · Mar 15, 2024 Risk: low
  GH Research PLC announced its participation in the Stifel 2024 Virtual CNS Days, scheduled for March 19-20, 2024. The company will engage in a fireside chat and
• GH Research PLC Files 20-F for Fiscal Year Ended December 31, 2023 — 20-F · Mar 7, 2024 Risk: low
  GH Research PLC (GHRS) filed a Foreign Annual Report (20-F) with the SEC on March 7, 2024. GH Research PLC filed its annual report on Form 20-F for the fiscal y
• GH Research to Present at TD Cowen Health Care Conference — 6-K · Feb 29, 2024 Risk: low
  GH Research PLC announced on February 29, 2024, that it will participate in the 44th Annual TD Cowen Health Care Conference from March 4-6, 2024, in Boston, Mas
• SC 13G Filing — SC 13G · Feb 16, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G Filing — SC 13G · Feb 14, 2024

Risk Profile

Risk Assessment: Of GHRS's 39 recent filings, 0 were flagged as high-risk, 10 as medium-risk, and 29 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

• Sanjay J. Mathew
• Lisa Harding
• Prof. Wiesław J. Cubała
• Dr. Fabian Devlin
• Prof. Bernhard T. Baune
• PD Dr. med. Philipp Ritter
• Florian Schönharting
• Michael E. Thase
• Julie Ryan
• Wieslaw J. Cubala

Industry Context

GH Research PLC operates within the Pharmaceutical Preparations industry, as indicated by its SIC code 2834.

Top Tags

conference-participation (9) · investor-relations (8) · conference-presentation (6) · 6-K (5) · pharmaceutical (5) · pharmaceuticals (4) · corporate-governance (4) · conference (4) · clinical-trial (3) · drug-development (3)

Key Numbers

• ECNP Meeting Edition: 38th — Indicates the significance and established nature of the conference.
• Reporting Period: Q1 2025 — Financial data presented for this period.
• Previous Full Year: FY 2024 — Comparative financial data provided.
• Fiscal Year End: 2024-12-31 — The reporting period covered by the 20-F filing.
• Previous Fiscal Year End: 2023-12-31 — Provides a comparative point for financial performance.
• Prior Fiscal Year End: 2022-12-31 — Offers a longer-term view of financial trends.
• Ordinary Shares Offered: 10,000,000 — Represents the volume of the completed share offering.
• Public Offering: $150 million — Capital raised by GH Research PLC
• Reporting Period End Date: 2024-06-30 — Indicates the end of the financial period covered by the filing.
• Prior Year End Date: 2023-12-31 — Provides a comparative point for financial analysis.
• Previous Year End Date: 2022-12-31 — Offers further historical financial context.
• Stifel European Healthcare Summit Dates: June 25-27, 2024 — Dates of the first conference where GH Research PLC will present.
• H.C. Wainwright Neuro Perspectives Conference Date: June 27, 2024 — Date of the second conference where GH Research PLC will present.
• Prior Year Period: 2023 — Comparative financial data for the full year 2023 is included.
• Event Dates: March 19-20, 2024 — Dates for the Stifel 2024 Virtual CNS Days

Frequently Asked Questions